bcl-2 and p53 in Prostate Cancer
Author Information
Author(s): I Apakama, MC Robinson, NM Walter, RG Charlton, JA Royds, CE Fuller, DE Neal, FC Hamdy
Primary Institution: University Urology Unit, Newcastle upon Tyne
Hypothesis
The study investigates the significance of bcl-2 protein overexpression and p53 nuclear protein accumulation in predicting hormone resistance in prostate cancer.
Conclusion
The combined detection of p53 protein accumulation and bcl-2 overexpression may help predict hormone resistance in prostate cancer.
Supporting Evidence
- 37 out of 77 cancers (48%) showed bcl-2 overexpression at diagnosis.
- 20 out of 27 patients with bcl-2 overexpression treated with hormone manipulation had hormone-refractory disease (74%).
- 14 out of 21 patients with p53 accumulation treated with hormones showed hormone resistance (66.6%).
- 81.2% of patients with both bcl-2 overexpression and p53 accumulation had hormone-refractory disease.
Takeaway
This study looked at how two proteins, bcl-2 and p53, can help doctors understand if prostate cancer will resist hormone treatment.
Methodology
The study involved immunohistochemistry to assess bcl-2 and p53 expression in prostate cancer tissues from 77 men.
Limitations
The study did not collect tissue from hormonally treated men for ethical reasons.
Participant Demographics
Participants were 77 men aged 46 to 88 years (median 71 years) with histologically proven prostate cancer.
Statistical Information
P-Value
P<0.0001
Statistical Significance
p<0.0001
Want to read the original?
Access the complete publication on the publisher's website